Knovea, a unit of Symbiotec Pharmalab, signed a deal with a global drugmaker to sell two injectable products in the US.

The agreement is dated 30 September. The partner is described only as a leading global pharma company, so its name is not yet public.

The two products come in dual chamber vials. Each vial has two compartments.

One holds the medicine and the other holds the liquid it is mixed with, and the two stay apart until the dose is needed.

Under the deal, the partner gets exclusive rights to sell both products in the US. Knovea keeps the work behind the scenes. It will develop the products, file the regulatory paperwork and manufacture them.

Money will come in two ways. Knovea gets payments as it hits set milestones, followed by a share of the profits. The US market open to these two products is estimated at $288 million.

The deal draws on Knovea’s sterile injectables facility, which has capacity for 20 million double chamber vials a year. Regulatory work is already under way.

Symbiotec filed its first generic drug application with the US FDA for a dual chamber vial product in September. A second filing is planned for early in the January to March quarter of 2027.

Separately, the US FDA has sent Symbiotec its inspection report for the Pithampur plant in Madhya Pradesh, following an inspection held in August.

The rating is Voluntary Action Indicated. That means inspectors noted issues that do not call for enforcement action, though the company is expected to fix them on its own.

Symbiotec itself is a new name on the market. It listed on NSE and BSE on 1 September, raising Rs 150 crore through a fresh issue and Rs 1,607 crore through an offer for sale.

The two products have not been named, and no launch date has been given. Neither the milestone amounts nor the profit split have been disclosed.

Feeling overwhelmed by the markets? Let Tradz by EquityPandit be your guide. Our user-friendly app simplifies complex data and provides actionable trading signals. Download the app today and trade with confidence!